Abcodia | detecting cancer earlier
detecting cancer earlier


Abcodia Serum BankConventional approaches to biomarker discovery use clinical samples from symptomatic patients. But, the discovery and validation of novel screening biomarkers requires samples that significantly precede diagnosis.

Between 2001 and 2005 over 202,600 women volunteers were enrolled into the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Volunteers donated a serum sample on trial entry and 50,000 women have continued to donate serum annually for up to 10 years.

Abcodia has the exclusive commercial rights to this biobank. The serum is collected to a rigorous protocol and is stored in liquid nitrogen at a commercial biobanking facility.

Abocodia Serum BankExtensive disease history

In addition to the samples, each volunteer has also provided information about demographics, lifestyle, and disease history and morphology.

Disease information is collected through the NHS Information Centre for Health and Social Care, Hospital Episode Statistics and death certificates. This data can be supplemented with additional disease data from UK General Practice and hospital medical records.

We can also match healthy volunteers, with benign and in-situ tumours as well as other diseases that are known to interact with a potential biomarker.

Consented ethical approach

Volunteers have given their informed consent for the samples and data to be used for medical research (including research undertaken in collaboration with commercial organisations)

Entry Criteria
>50 years old, post-menopausal
Free from active cancer
No cancer history in previous 12 months
Volunteer data
Demographic and lifestyle information
NHS Information Centre for Health and Social Care (ONS)
NHS Hospital Episode Statistics records
GP and Consultant completed reports on outcomes and medical history